Lung Cancer | Specialty

Dr. Peters Discusses Ongoing Research With Trastuzumab Deruxtecan in NSCLC

July 2nd 2020

Solange Peters, MD,​ PhD, discusses ongoing research with ​fam-trastuzumab deruxtecan​-nxki (Enhertu; ​DS-8201) in patients with HER2-mutated non–small cell lung cancer.

Capmatinib Approved in Japan for METex14-Altered Advanced NSCLC

June 29th 2020

The Japanese Ministry of Health, Labor, and Welfare has approved capmatinib for patients with MET exon 14 skipping mutation–positive advanced and/or recurrent unresectable non–small cell lung cancer.

DESTINY-Lung01 Data Position Trastuzumab Deruxtecan as Next Oncogene-Driven Therapy in NSCLC

June 29th 2020

Nathan A. Pennell, MD, PhD, discusses the significance of findings from the DESTINY-Lung01 trial in non–small cell lung cancer.

Liu Lends Insight on Highlights From ASCO 2020 in Lung Cancer

June 25th 2020

A number of influential clinical trials were presented during the 2020 ASCO Virtual Scientific Program, 8 of which Stephen Liu, MD, discusses in depth in a virtual presentation during the 2020 ASCO Direct Highlights webcast.

Nivolumab/Ipilimumab Demonstrates OS Benefit in Advanced NSCLC With Brain Metastases

June 24th 2020

The combination of nivolumab and ipilimumab provided similar clinical benefit to that of chemotherapy when given as a frontline treatment for patients with advanced non–small cell lung cancer who had stable and treated brain metastases at baseline.

Tiragolumab/Atezolizumab Shows Early First-in-Human Efficacy in Frontline PD-L1+ NSCLC

June 24th 2020

Tiragolumab in combination with atezolizumab (Tecentriq) demonstrated early clinical activity and was found to be well tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer who were PD-L1 positive and had not received prior checkpoint inhibition.

Dr. Horn on Updated IMpower133 Data in Small Cell Lung Cancer

June 23rd 2020

Leora Horn, MD, MSc, discusses data from an updated analysis of the phase 3 IMpower133 trial, which examined the first-line combination of atezolizumab (Tecentriq), carboplatin, and etoposide in small cell lung cancer.

Utility of Minimally Invasive Plasma-Based NGS Expands in NSCLC

June 23rd 2020

Plasma-based next-generation sequencing continues to offer a minimally invasive, highly specific modality to identify patients with actionable alterations in non–small cell lung cancer.

ctDNA Clearance Shows Correlation With PFS Improvement in EGFR+/MET+ NSCLC

June 23rd 2020

Circulating tumor DNA clearance of EGFR mutation may be predictive of prolonged progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung cancer with detectable ctDNA at baseline.

Rapid Readouts: Three-Year Update From CheckMate 227, Part 1

June 23rd 2020

Rapid Readouts: Final Analysis of KEYNOTE-189

June 23rd 2020

Dr. Halmos on Recent Advancements in Non–Small Cell Lung Cancer

June 23rd 2020

Balazs Halmos, MD, MS, discusses recent advancements made in non–small cell lung cancer.

Tislelizumab Application Accepted in China for Frontline Advanced NSCLC

June 23rd 2020

The China National Medical Products Administration has accepted a supplemental new drug application for tislelizumab in combination with chemotherapy for the frontline treatment of patients with advanced nonsquamous non–small cell lung cancer.

Atezolizumab Regimen Improves OS in Frontline Extensive-Stage Small Cell Lung Cancer, Regardless of Biomarker Status

June 22nd 2020

The combination of atezolizumab plus carboplatin/etoposide continued to demonstrate an improvement in overall survival versus chemotherapy alone as a frontline treatment for patients with extensive-stage small cell lung cancer.

Dr. Rintoul on the Importance of MRD Assessment in NSCLC

June 22nd 2020

Robert Rintoul, BSc, MB ChB, PhD, FRCP, discusses the importance of minimal residual disease assessment in patients with non–small cell lung cancer.

Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer

June 22nd 2020

In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

Rapid Readouts: CheckMate 9LA

June 16th 2020

Adjuvant Osimertinib On Way to Becoming New Standard in EGFR-Mutant NSCLC

June 16th 2020

Roy S. Herbst MD, PhD, discusses the ADAURA trial and the impressive data seen with adjuvant osimertinib and highlights ongoing research efforts being made with the agent in lung cancer.

NICE Recommends Entrectinib for ROS1+ Advanced NSCLC

June 16th 2020

The United Kingdom’s National Institute for Health and Care Excellence has recommended entrectinib (Rozlytrek) as a treatment option for ROS1-positive advanced non–small cell lung cancer in adults who have not received prior treatment with ROS1 inhibitors.

FDA Approves Lurbinectedin for Metastatic Small Cell Lung Cancer

June 15th 2020

The FDA has approved lurbinectedin (Zepzelca) for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy.